Get started
Author

W Reinisch

Observed name: Walter Reinisch
OpenAlex ID: A5123516690
OP20 Results from the STENOVA trial: A Phase 2a, randomized, placebo-controlled, double-blind study to assess the safety, pharmacokinetics (PK), and pharmacodynamics of ontunisertib (AGMB-129) in patients with Fibrostenotic Crohn’s Disease (FSCD)
2026 · F Rieder, B G Feagan, et al. · Journal of Crohn s and Colitis · 2
P0931 Endoscopic responsiveness of the updated Rutgeerts score and its components to treatment in clinical postoperative recurrence
2026 · J Simonič, P Simonič, et al. · Journal of Crohn s and Colitis · 1
PDF
Histologic and combined histologic–endoscopic outcomes with mirikizumab in Crohn’s disease: VIVID-1 trial results
2026 · Vipul Jairath, Fernando Magro, et al. · Journal of Crohn s and Colitis
A Comparison of Vedolizumab and Ustekinumab as second line therapy in anti-TNF-failed patients with Crohn’s disease – a national, multicenter, retrospective study
2026 · M Bäuerle, W Reinisch, et al. · Zeitschrift für Gastroenterologie
Subcutaneous Mirikizumab Maintenance Treatment Over 40 Weeks Leads to Incremental Improvements in Rates of Clinical Remission and Endoscopic Response: Results from the Phase 3 VIVID-1 Study
2026 · P Bossuyt, D Laharie, et al. · Zeitschrift für Gastroenterologie
Mirikizumab Demonstrates Long-Term Efficacy on Histological Resolution in the Phase 3, Multicenter, Open-Label VIVID-2 Extension Study
2026 · W Reinisch, V Jairath, et al. · Zeitschrift für Gastroenterologie
P1043 Unsupervised machine learning to identify distinct CDAI-based response patterns to guselkumab in participants with Crohn’s disease: Post hoc analysis of the pooled GRAVITI and GALAXI 2/3 studies
2026 · S W Schreiber, G D’Haens, et al. · Journal of Crohn s and Colitis
DOP036 Real-world corticosteroid use in patients with Ulcerative Colitis receiving filgotinib up to week 24: An interim analysis from the prospective, observational GALOCEAN study
2026 · S W Schreiber, M Löwenberg, et al. · Journal of Crohn s and Colitis
PDF
P0398 AI-enabled endoscopy and quantitative histology provide novel insights into relationship between macroscopic and microscopic inflammation in Ulcerative Colitis
2026 · W Reinisch, D T Rubin, et al. · Journal of Crohn s and Colitis
P1068 Real-world effectiveness of filgotinib by prior advanced treatment and predictors of clinical response in Ulcerative Colitis: Interim results up to week 24 from the prospective, observational GALOCEAN study
2026 · W Reinisch, M Löwenberg, et al. · Journal of Crohn s and Colitis
PDF
P0565 Mirikizumab induction response is associated with molecular and cellular-based tissue archetype features of mucosal recovery in ulcerative colitis
2026 · N Fernandes, O Sharma, et al. · Journal of Crohn s and Colitis
P0214 Lesions at the ileal inlet are most predictive of Crohn’s disease postoperative recurrence
2026 · J Simonič, P Simonič, et al. · Journal of Crohn s and Colitis
DOP075 Mirikizumab mediates clinical benefit through distinct mucosal cellular mechanisms in Crohn’s disease.
2026 · B Steere, D Jain, et al. · Journal of Crohn s and Colitis
Das Therapieansprechen auf systemische Kortikosteroide bei Patienten mit aktiver Colitis ulcerosa ist mit der Regeneration des Mikrobioms und erhöhter mikrobielle Butyratproduktion assoziiert
2022 · A Blesl, P Wurm, et al. · Zeitschrift für Gastroenterologie
Postoperative Immunsupression zeigt keinen Einfluss auf das endoskopische Rezidiv nach Darmresektionen bei PatientInnen mit Morbus Crohn- Eine retrospektive multizentrische Datenauswertung
2022 · N Pfisterer, T Dengler, et al. · Zeitschrift für Gastroenterologie
Wirksamkeit und Sicherheit von magensaftresistentem Phosphatidylcholin-Granulat (LT-02) in der Remissionsinduktion bei Colitis ulcerosa Patienten mit ungenügendem Ansprechen auf Mesalazin: eine randomisierte, doppelblinde, Plazebo-kontrollierte Studie
2018 · A Dignaß, W Reinisch, et al. · Zeitschrift für Gastroenterologie
Works count: 16
Citation count: 3
H-index: 1
I10-index:
Year
Topic
Type